Digital Delivery of Alzheimer's Genetic and Blood Test Results Matches Telehealth Visits for Distress
In the randomized eSMARTER trial, learning APOE and p-tau217 results through a digital platform was noninferior to a telehealth visit on anxiety, distress and knowledge.
Summary
Alzheimer's risk testing is moving into routine care, and results often reach patients as a static portal report. The randomized eSMARTER trial asked whether a patient-centered digital platform could replace a clinician telehealth visit for disclosing APOE genotype and, later, the blood biomarker p-tau217. In 651 adults aged 60 to 80, one to 7 days after disclosure, anxiety, disease-specific distress and disease-related knowledge met noninferiority in the digital arm compared with telehealth. Results were similar for p-tau217. Among APOE4 carriers, three differences emerged between arms, including a greater reduction in disease-specific distress with telehealth; the available text cuts off before listing the rest. This is a trial of how results are communicated and short-term psychological response, not of any treatment, and it does not show effects on cognition or lifespan.
Detailed Summary
Blood and genetic tests for Alzheimer's risk are becoming easier to order, and under the 21st Century Cures Act most results must be released to patients immediately. In practice, many people see a PDF in a patient portal with little context and wait for a follow-up appointment. The question for clinicians is whether a well-designed digital tool can deliver this sensitive information safely.
The eSMARTER randomized trial, presented at the Clinical Trials on Alzheimer's Disease conference and published in JAMA Neurology, tested exactly that. Participants were 60 to 80 years old, had prior APOE genotyping without disclosure through the GeneMatch program, passed psychological screening and had internet access. Mean age was 68, 67% were women, and mean MoCA score was 19, with about 36% below 19. A total of 216 were randomized to clinician-mediated telehealth disclosure and 435 to digital disclosure. All were offered optional educational materials. After 6 months, participants could choose to learn their plasma p-tau217 result by the same method.
Of 651 people who received APOE results, 58% were heterozygous carriers of APOE4, 10% homozygous and 32% noncarriers. One to 7 days after disclosure, anxiety, disease-specific distress and knowledge met noninferiority for digital versus telehealth, and p-tau217 disclosure showed similar results. Overall there were no differences between arms. Among APOE4 carriers, three differences appeared, including a larger reduction in disease-specific distress with telehealth; the remaining two are not in the excerpt.
Practically, the findings support scalable digital disclosure as a reasonable option, which could reduce delays and clinician burden as biomarker testing expands. Telehealth may still suit APOE4 carriers who want personal support.
Caveats are important. The sample was selected: motivated research registry participants with internet access who passed psychological screening, and who had chosen genotyping. Outcomes were measured within days, so longer-term effects are unknown. The trial examined communication and psychological response, not whether testing improves health outcomes. The article text is truncated, so details should be checked in the publication.
Key Findings
- Randomized eSMARTER trial: 651 adults aged 60-80 received APOE results by digital platform (435) or clinician telehealth (216).
- Anxiety, disease-specific distress and knowledge met noninferiority for digital versus telehealth 1-7 days after APOE disclosure.
- Similar noninferiority results were reported for optional p-tau217 blood biomarker disclosure after 6 months.
- Among APOE4 carriers, three differences emerged, including greater distress reduction with telehealth; the other two were not in the excerpt.
- The trial measured short-term psychological outcomes only; it did not test cognition, treatment effects or lifespan.
Methodology
This is a MedPage Today conference news report on a randomized noninferiority trial (eSMARTER), also published in JAMA Neurology. Enrollment was 651 participants, unevenly allocated 216 telehealth to 435 digital. Endpoints were anxiety, disease-specific distress and knowledge at 1-7 days; the p-tau217 portion was an optional follow-on, not a randomization of all participants.
Study Limitations
The excerpt is cut off, so two of three APOE4 carrier differences and any effect sizes or noninferiority margins are unavailable; verify in JAMA Neurology. Participants were screened, registry-enrolled and internet-capable, limiting generalizability, and follow-up was only days. The p-tau217 arm involved self-selection, and the trial says nothing about downstream health outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
